{"id":6725,"date":"2026-03-11T17:50:26","date_gmt":"2026-03-11T14:50:26","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=6725"},"modified":"2026-03-17T11:53:35","modified_gmt":"2026-03-17T08:53:35","slug":"biomarkers-in-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/biomarkers-in-duchenne-muscular-dystrophy\/","title":{"rendered":"NSAA Tek Ba\u015f\u0131na Yeterli De\u011fil: Kreatin Kinaz (CK), AST, ALT ve Distrofin D\u00fczeylerinin A\u00e7\u0131klanmas\u0131 Neden \u00d6nemli?"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Peki neden bir\u00e7ok DMD klinik \u00e7al\u0131\u015fmas\u0131 bu \u00f6nemli biyobelirte\u00e7leri a\u00e7\u0131k\u00e7a bildirmekten ka\u00e7\u0131n\u0131yor? <strong>Bu makale, CK, AST, ALT ve distrofin verilerinin neden \u00f6nemli oldu\u011funu ve tedavi se\u00e7eneklerini ara\u015ft\u0131ran ailelerin neden tam \u015feffafl\u0131k talep etmesi gerekti\u011fini inceliyor.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (DMD), distrofin genindeki mutasyonlardan kaynaklanan ilerleyici kas dejenerasyonu ile karakterize edilen, en y\u0131k\u0131c\u0131 genetik n\u00f6rom\u00fcsk\u00fcler bozukluklardan biridir. Son on y\u0131lda, distrofin ekspresyonunu geri kazand\u0131rmay\u0131 veya k\u0131smen de\u011fi\u015ftirmeyi ama\u00e7layan gen terapileri ve ekzon atlama ila\u00e7lar\u0131n\u0131n geli\u015ftirilmesiyle tedavi alan\u0131 h\u0131zla geli\u015fmi\u015ftir. <strong>Bu tedaviler genellikle Kuzey Y\u0131ld\u0131z\u0131 Ayakta Tedavi De\u011ferlendirmesi (NSAA) gibi fonksiyonel sonu\u00e7lar\u0131 bildiren klinik \u00e7al\u0131\u015fmalar arac\u0131l\u0131\u011f\u0131yla de\u011ferlendirilir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NSAA, Duchenne kas distrofisi olan y\u00fcr\u00fcyebilen erkek \u00e7ocuklarda motor yetene\u011fin \u00f6nemli bir fonksiyonel \u00f6l\u00e7\u00fcm\u00fcn\u00fc sa\u011flasa da, yaln\u0131zca bu \u00f6l\u00e7\u00fcme g\u00fcvenmek yan\u0131lt\u0131c\u0131 olabilir. Klinik iyile\u015fmeler (veya iyile\u015fme olmamas\u0131) b\u00fcy\u00fcme, steroid tedavisi veya hastal\u0131\u011f\u0131n ilerlemesindeki do\u011fal de\u011fi\u015fkenlikten etkilenebilir. <strong>Duchenne kas distrofisinde kreatin kinaz (CK), alanin aminotransferaz (ALT), aspartat aminotransferaz (AST) ve distrofin protein d\u00fczeyleri gibi biyobelirte\u00e7ler, hastal\u0131k aktivitesi ve tedavi etkisine dair temel biyokimyasal kan\u0131tlar sa\u011flar.<\/strong> Devam\u0131n\u0131 oku:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-creatine-kinase-ck\/\" target=\"_blank\" rel=\"noreferrer noopener\">Kreatin Kinaz (CK) Nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00d6nemlerine ra\u011fmen, bir\u00e7ok klinik \u00e7al\u0131\u015fma ve \u015firket bas\u0131n b\u00fclteni, genellikle ayr\u0131nt\u0131l\u0131 biyokimyasal \u00f6l\u00e7\u00fcmleri ihmal ederek, fonksiyonel sonu\u00e7lara vurgu yaparak, s\u0131n\u0131rl\u0131 biyobelirte\u00e7 verisi sunmaktad\u0131r.<\/strong> Bu \u015feffafl\u0131k eksikli\u011fi, klinisyenler, ara\u015ft\u0131rmac\u0131lar, d\u00fczenleyiciler ve Duchenne toplulu\u011fu i\u00e7in \u00f6nemli endi\u015feler do\u011furmaktad\u0131r.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#duchenne-muscular-dystrophy-why-biomarkers-matter\">Duchenne Kas Distrofisinde Biyobelirte\u00e7ler<\/a><\/li><li><a href=\"#the-dominance-of-functional-measures-in-duchenne-trials\">Duchenne \u00c7al\u0131\u015fmalar\u0131nda Fonksiyonel \u00d6l\u00e7\u00fcmlerin Bask\u0131nl\u0131\u011f\u0131<\/a><\/li><li><a href=\"#gene-therapy-and-exon-skipping-treatments-a-new-era\">Gen Terapisi ve Ekzon Atlama Tedavileri: Yeni Bir \u00c7a\u011f<\/a><\/li><li><a href=\"#the-problem-limited-reporting-of-duchenne-biomarkers-data\">Sorun: Duchenne Biyobelirte\u00e7leri Verilerinin S\u0131n\u0131rl\u0131 \u015eekilde Raporlanmas\u0131<\/a><ul><li><a href=\"#1-lack-of-mechanistic-evidence\">1. Mekanistik Kan\u0131t Eksikli\u011fi<\/a><\/li><li><a href=\"#2-difficulty-comparing-therapies\">2. Tedavileri Kar\u015f\u0131la\u015ft\u0131rmada Zorluk<\/a><\/li><li><a href=\"#3-reduced-scientific-transparency\">3. Bilimsel \u015eeffafl\u0131\u011f\u0131n Azalmas\u0131<\/a><\/li><\/ul><\/li><li><a href=\"#duchenne-biomarkers-provide-early-signals-of-efficacy\">Duchenne Biyobelirte\u00e7leri Etkinli\u011fe Dair Erken Sinyaller Sa\u011fl\u0131yor<\/a><\/li><li><a href=\"#monitoring-safety-ast-and-alt\">G\u00fcvenli\u011fin \u0130zlenmesi: AST ve ALT<\/a><\/li><li><a href=\"#dystrophin-the-most-important-biomarker\">Distrofin: En \u00d6nemli Biyobelirte\u00e7<\/a><\/li><li><a href=\"#when-functional-outcomes-and-biomarkers-do-not-align\">Fonksiyonel Sonu\u00e7lar ve Biyobelirte\u00e7ler Uyumsuz Oldu\u011funda<\/a><\/li><li><a href=\"#the-role-of-regulatory-agencies\">D\u00fczenleyici Kurumlar\u0131n Rol\u00fc<\/a><\/li><li><a href=\"#the-patient-perspective\">Hasta Bak\u0131\u015f A\u00e7\u0131s\u0131<\/a><\/li><li><a href=\"#the-need-for-standardized-biomarker-reporting\">Biyobelirte\u00e7 Raporlamas\u0131n\u0131n Standartla\u015ft\u0131r\u0131lmas\u0131na Duyulan \u0130htiya\u00e7<\/a><\/li><li><a href=\"#toward-greater-transparency-in-duchenne-research\">Duchenne Ara\u015ft\u0131rmalar\u0131nda Daha Fazla \u015eeffafl\u0131\u011fa Do\u011fru<\/a><\/li><li><a href=\"#frequently-asked-questions-faq-about-duchenne-clinical-trials-and-biomarkers\">Duchenne Klinik \u00c7al\u0131\u015fmalar\u0131 ve Biyobelirte\u00e7leri Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular (SSS)<\/a><ul><li><a href=\"#faq-question-1773236242350\">Duchenne kas distrofisi klinik \u00e7al\u0131\u015fmalar\u0131nda biyobelirte\u00e7ler neden \u00f6nemlidir?<\/a><\/li><li><a href=\"#faq-question-1773236258234\">Kreatin kinaz (CK) nedir ve Duchenne kas distrofisinde neden \u00f6nemlidir?<\/a><\/li><li><a href=\"#faq-question-1773236281023\">Duchenne kas distrofisi hastalar\u0131nda AST ve ALT d\u00fczeyleri neden s\u0131kl\u0131kla y\u00fcksektir?<\/a><\/li><li><a href=\"#faq-question-1773236299747\">Dystrofin nedir ve Duchenne kas distrofisi tedavilerinde neden \u00f6nemlidir?<\/a><\/li><li><a href=\"#faq-question-1773236320298\">Baz\u0131 klinik ara\u015ft\u0131rma duyurular\u0131n\u0131n neden \u00e7o\u011funlukla NSAA puanlar\u0131na odaklanmas\u0131n\u0131n sebebi nedir?<\/a><\/li><li><a href=\"#faq-question-1773236346480\">Tedavi i\u015fe yaramasa bile NSAA puanlar\u0131 iyile\u015febilir mi?<\/a><\/li><li><a href=\"#faq-question-1773236364060\">Baz\u0131 klinik ara\u015ft\u0131rmalar neden ayr\u0131nt\u0131l\u0131 biyobelirte\u00e7 sonu\u00e7lar\u0131n\u0131 yay\u0131nlam\u0131yor?<\/a><\/li><li><a href=\"#faq-question-1773236373471\">Klinik \u00e7al\u0131\u015fmalarda distrofin d\u00fczeyleri nas\u0131l \u00f6l\u00e7\u00fcl\u00fcr?<\/a><\/li><li><a href=\"#faq-question-1773236409734\">D\u00fc\u015f\u00fck CK seviyeleri Duchenne tedavisinin i\u015fe yarad\u0131\u011f\u0131 anlam\u0131na m\u0131 gelir?<\/a><\/li><li><a href=\"#faq-question-1773236430411\">Aileler klinik ara\u015ft\u0131rma sonu\u00e7lar\u0131 hakk\u0131nda yaln\u0131zca bas\u0131n b\u00fcltenlerine mi g\u00fcvenmeli?<\/a><\/li><li><a href=\"#faq-question-1773236472719\">Aileler, Duchenne kas distrofisi klinik deneme sonu\u00e7lar\u0131n\u0131 de\u011ferlendirirken nelere dikkat etmelidir?<\/a><\/li><li><a href=\"#faq-question-1773236513181\">Gelecekteki Duchenne \u00e7al\u0131\u015fmalar\u0131nda biyobelirte\u00e7 raporlamas\u0131 daha yayg\u0131n hale gelecek mi?<\/a><\/li><\/ul><\/li><li><a href=\"#final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/a><\/li><li><a href=\"#sources-and-academic-references\">Kaynaklar ve Akademik Referanslar<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"duchenne-muscular-dystrophy-why-biomarkers-matter\">Duchenne Kas Distrofisinde Biyobelirte\u00e7ler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi, distrofin genindeki mutasyonlardan kaynaklan\u0131r ve kas liflerinde distrofin proteininin yoklu\u011funa veya ciddi derecede yetersizli\u011fine yol a\u00e7ar.<\/strong> Distrofin olmadan, kas h\u00fccreleri kas\u0131lma s\u0131ras\u0131nda hasara kar\u015f\u0131 son derece hassas hale gelir ve bu da tekrarlayan dejenerasyon ve rejenerasyon d\u00f6ng\u00fclerine yol a\u00e7ar. Daha fazla bilgi i\u00e7in:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dystrophin-gene\/\" target=\"_blank\" data-type=\"post\" data-id=\"3785\" rel=\"noreferrer noopener\">Distrofin geni nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Biyobelirte\u00e7ler, DMD&#039;de hastal\u0131k aktivitesini ve tedavi etkilerini anlamak i\u00e7in hayati \u00f6neme sahiptir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u015fl\u0131ca biyobelirte\u00e7ler \u015funlard\u0131r:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kreatin Kinaz (CK)<\/strong><br>CK, kas h\u00fccreleri hasar g\u00f6rd\u00fc\u011f\u00fcnde kan dola\u015f\u0131m\u0131na sal\u0131nan bir kas enzimidir. Y\u00fcksek CK seviyeleri, DMD&#039;nin en erken biyokimyasal g\u00f6stergelerinden biridir ve devam eden kas hasar\u0131n\u0131 yans\u0131t\u0131r. <sup data-fn=\"a8963fdf-1c4d-4eae-b955-4fcf316dd517\" class=\"fn\"><a id=\"a8963fdf-1c4d-4eae-b955-4fcf316dd517-link\" href=\"#a8963fdf-1c4d-4eae-b955-4fcf316dd517\">1<\/a><\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AST ve ALT<\/strong><br>Genellikle karaci\u011fer enzimleri olarak kullan\u0131lmalar\u0131na ra\u011fmen, AST ve ALT Duchenne kas y\u0131k\u0131m\u0131 nedeniyle de y\u00fckselir. Bu enzimlerdeki de\u011fi\u015fiklikler kas korumas\u0131n\u0131 veya tedavi etkilerini yans\u0131tabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distrofin Seviyesi<\/strong><br>Modern Duchenne tedavilerinin \u00e7o\u011funun nihai terap\u00f6tik hedefi, distrofin ekspresyonunu geri kazand\u0131rmakt\u0131r. Kas biyopsilerinde distrofin seviyelerinin \u00f6l\u00e7\u00fclmesi, bir tedavinin molek\u00fcler d\u00fczeyde i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131n do\u011frudan kan\u0131t\u0131n\u0131 sa\u011flar.<a href=\"https:\/\/link.springer.com\/article\/10.1007\/s11897-022-00541-6\" target=\"_blank\" rel=\"noreferrer noopener\">Springer<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu biyobelirte\u00e7ler birlikte, tedavilerin hastal\u0131k biyolojisini de\u011fi\u015ftirip de\u011fi\u015ftirmedi\u011fine dair biyokimyasal bir do\u011frulama sa\u011flar.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-dominance-of-functional-measures-in-duchenne-trials\">Duchenne \u00c7al\u0131\u015fmalar\u0131nda Fonksiyonel \u00d6l\u00e7\u00fcmlerin Bask\u0131nl\u0131\u011f\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">G\u00fcn\u00fcm\u00fczdeki bir\u00e7ok Duchenne \u00e7al\u0131\u015fmas\u0131, a\u015fa\u011f\u0131daki gibi fonksiyonel sonu\u00e7 noktalar\u0131na odaklanmaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/dmdwarrior.com\/tr\/north-star-ambulatory-assessment-nsaa-in-duchenne-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Kuzey Y\u0131ld\u0131z\u0131 Ayaktan De\u011ferlendirme (NSAA)<\/a><\/li>\n\n\n\n<li>Alt\u0131 dakikal\u0131k y\u00fcr\u00fcme testi (6MWT)<\/li>\n\n\n\n<li>Aya\u011fa kalkma veya merdiven \u00e7\u0131kma zaman\u0131<\/li>\n\n\n\n<li>Zamanl\u0131 motor fonksiyon testleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00f6l\u00e7\u00fcmler \u00f6nemlidir \u00e7\u00fcnk\u00fc hastalar\u0131n fiziksel yeteneklerini do\u011frudan yans\u0131t\u0131rlar. Bununla birlikte, tedavinin kendisiyle ilgisi olmayan fakt\u00f6rlerden de etkilenirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>K\u00fc\u00e7\u00fck \u00e7ocuklarda normal geli\u015fim nedeniyle ge\u00e7ici iyile\u015fmeler g\u00f6r\u00fclebilir.<\/li>\n\n\n\n<li>Y\u00fcksek doz kortikosteroidler kas g\u00fcc\u00fcn\u00fc ve fonksiyonunu iyile\u015ftirebilir.<\/li>\n\n\n\n<li>K\u0131sa vadeli fonksiyonel iyile\u015fmeler, uzun vadeli hastal\u0131k de\u011fi\u015fimini yans\u0131tmayabilir.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rmac\u0131lar, erken evre denemeler s\u0131ras\u0131nda NSAA puanlar\u0131ndaki iyile\u015fmelerin dikkatli yorumlanmas\u0131 gerekti\u011fini defalarca belirtmi\u015flerdir; \u00e7\u00fcnk\u00fc tedavi g\u00f6rmeyen gen\u00e7 hastalar do\u011fal b\u00fcy\u00fcme nedeniyle ge\u00e7ici fonksiyonel kazan\u0131mlar da g\u00f6sterebilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu nedenle Duchenne kas distrofisinde biyobelirte\u00e7ler, tamamlay\u0131c\u0131 kan\u0131t olarak b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"gene-therapy-and-exon-skipping-treatments-a-new-era\">Gen Terapisi ve Ekzon Atlama Tedavileri: Yeni Bir \u00c7a\u011f<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Son y\u0131llarda Duchenne kas distrofisi i\u00e7in tedavi y\u00f6ntemlerinde b\u00fcy\u00fck bir geli\u015fme ya\u015fand\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunlar aras\u0131nda \u015funlar yer almaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AAV tabanl\u0131 mikro-distrofin gen terapileri<\/strong><\/li>\n\n\n\n<li><strong>Antisens ekzon atlama terapileri<\/strong><\/li>\n\n\n\n<li><strong>Gen d\u00fczenleme yakla\u015f\u0131mlar\u0131<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon atlama terapileri, distrofin transkriptini de\u011fi\u015ftirerek daha k\u0131sa ancak k\u0131smen i\u015flevsel bir protein \u00fcretmeyi ama\u00e7lar. Bu terapiler genellikle belirli mutasyonlar\u0131 hedef al\u0131r ve yaln\u0131zca hastalar\u0131n bir alt k\u00fcmesine fayda sa\u011flayabilir. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">Ekzon Atlama Nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tek doz AAV tabanl\u0131 mikrodistrofin gen terapileri, distrofin geninin i\u015flevsel bir versiyonunu tek bir tedaviyle hastalar\u0131n kaslar\u0131na iletmek \u00fczere tasarlanm\u0131\u015ft\u0131r. Erken d\u00f6nem deneme sonu\u00e7lar\u0131 genellikle North Star Ambulatory Assessment (NSAA) gibi fonksiyonel \u00f6l\u00e7\u00fcmlerde iyile\u015fmeleri vurgulasa da, bu testler tek ba\u015f\u0131na terapinin kas dokusunu ger\u00e7ekten koruyup korumad\u0131\u011f\u0131n\u0131 veya distrofini molek\u00fcler d\u00fczeyde geri kazand\u0131r\u0131p kazand\u0131rmad\u0131\u011f\u0131n\u0131 do\u011frulayamaz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisinde kreatin kinaz (CK), AST, ALT ve distrofin d\u00fczeyleri gibi biyobelirte\u00e7lerin ayr\u0131nt\u0131l\u0131 olarak raporlanmas\u0131 \u00e7ok \u00f6nemlidir \u00e7\u00fcnk\u00fc bu biyobelirte\u00e7ler kas sa\u011fl\u0131\u011f\u0131, devam eden dejenerasyon ve tedavi etkisine dair do\u011frudan biyokimyasal kan\u0131t sa\u011flar.<\/strong> CK d\u00fczeyleri kas hasar\u0131n\u0131n derecesini g\u00f6sterirken, AST ve ALT kas ve karaci\u011fer enzim aktivitesi hakk\u0131nda bilgi verir ve distrofin \u00f6l\u00e7\u00fcmleri tedavinin birincil molek\u00fcler hedefine ula\u015f\u0131p ula\u015fmad\u0131\u011f\u0131n\u0131 g\u00f6sterir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ara\u015ft\u0131rmalara kat\u0131lmay\u0131 d\u00fc\u015f\u00fcnen veya yeni onaylanm\u0131\u015f tedavilere eri\u015fimi de\u011ferlendiren aileler i\u00e7in \u015feffaf biyobelirte\u00e7 verileri, karar verme s\u00fcre\u00e7lerini \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir. Bir tedavinin CK, AST, ALT ve distrofin \u00fczerindeki etkisini anlamak, ailelerin potansiyel faydalar\u0131, viral vekt\u00f6r iletiminden kaynaklanabilecek ba\u011f\u0131\u015f\u0131kl\u0131k tepkileri veya karaci\u011fer toksisitesi gibi risklere kar\u015f\u0131 tartmalar\u0131na yard\u0131mc\u0131 olur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ayr\u0131nt\u0131l\u0131 biyobelirte\u00e7 bilgilerine eri\u015fim olmadan, aileler yaln\u0131zca fonksiyonel skorlara veya \u015firketlerin bas\u0131n b\u00fcltenlerine g\u00fcvenmek zorunda kal\u0131rlar; bu da tedavi etkinli\u011fini tam olarak yans\u0131tmayabilir.<\/strong> \u015eeffaf raporlama, ailelerin bilin\u00e7li se\u00e7imler yapmalar\u0131n\u0131, gerekli izlemeyi savunmalar\u0131n\u0131 ve tek doz AAV tabanl\u0131 gen terapilerinin beklenen sonu\u00e7lar\u0131 ve uzun vadeli etkileri hakk\u0131nda klinisyenlerle anlaml\u0131 bir \u015fekilde etkile\u015fim kurmalar\u0131n\u0131 sa\u011flar.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-problem-limited-reporting-of-duchenne-biomarkers-data\">Sorun: Duchenne Biyobelirte\u00e7leri Verilerinin S\u0131n\u0131rl\u0131 \u015eekilde Raporlanmas\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi klinik ara\u015ft\u0131rmalar\u0131 alan\u0131ndaki en endi\u015fe verici konulardan biri, sonu\u00e7lar\u0131n se\u00e7ici bir \u015fekilde raporlanmas\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok deneme g\u00fcncellemesi \u00f6ncelikle \u015fu konulara odaklanmaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>NSAA iyile\u015ftirmeleri<\/li>\n\n\n\n<li>Zamanl\u0131 fonksiyonel testler<\/li>\n\n\n\n<li>G\u00fcvenlik verileri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ancak genellikle minimal veya eksik biyobelirte\u00e7 verileri sa\u011flarlar.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin, \u015firket duyurular\u0131 i\u015flevsel iyile\u015ftirmeleri vurgulayabilir ancak \u015funlar\u0131 atlayabilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>zamana yay\u0131lm\u0131\u015f CK \u00f6l\u00e7\u00fcmleri<\/li>\n\n\n\n<li>detayl\u0131 AST\/ALT de\u011fi\u015fimleri<\/li>\n\n\n\n<li>bireysel distrofin ekspresyon seviyeleri<\/li>\n\n\n\n<li>hasta d\u00fczeyinde biyobelirte\u00e7 de\u011fi\u015fkenli\u011fi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu se\u00e7ici raporlama \u00e7e\u015fitli sorunlara yol a\u00e7\u0131yor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-lack-of-mechanistic-evidence\">1. Mekanistik Kan\u0131t Eksikli\u011fi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi verilerinde biyobelirte\u00e7ler olmadan, bir tedavinin altta yatan hastal\u0131k s\u00fcrecini ger\u00e7ekten de\u011fi\u015ftirip de\u011fi\u015ftirmedi\u011fini belirlemek zorla\u015f\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin, NSAA skorlar\u0131 iyile\u015firken CK seviyeleri de\u011fi\u015fmeden kal\u0131rsa, fonksiyonel iyile\u015fme steroid kullan\u0131m\u0131 veya plasebo etkileri gibi di\u011fer fakt\u00f6rlerden kaynaklan\u0131yor olabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-difficulty-comparing-therapies\">2. Tedavileri Kar\u015f\u0131la\u015ft\u0131rmada Zorluk<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi tedavisinde g\u00fcn\u00fcm\u00fczde \u00e7ok say\u0131da gen terapisi ve ekzon atlama ilac\u0131 yer almaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Standartla\u015ft\u0131r\u0131lm\u0131\u015f biyobelirte\u00e7 raporlamas\u0131 olmadan, tedavilerin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131 neredeyse imkans\u0131z hale gelir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"3-reduced-scientific-transparency\">3. Bilimsel \u015eeffafl\u0131\u011f\u0131n Azalmas\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ara\u015ft\u0131rmalar, ba\u011f\u0131ms\u0131z ara\u015ft\u0131rmac\u0131lar\u0131n sonu\u00e7lar\u0131 de\u011ferlendirebilmesi i\u00e7in yeterli veri sa\u011flamal\u0131d\u0131r. Biyobelirte\u00e7 bilgisi eksik veya yetersiz oldu\u011funda, bilimsel inceleme s\u0131n\u0131rlan\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"duchenne-biomarkers-provide-early-signals-of-efficacy\">Duchenne Biyobelirte\u00e7leri Etkinli\u011fe Dair Erken Sinyaller Sa\u011fl\u0131yor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisinde biyobelirte\u00e7ler, tedavinin i\u015fe yarad\u0131\u011f\u0131na dair en erken sinyalleri genellikle verir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin, CK seviyelerindeki azalma, tedavi sonras\u0131nda kas hasar\u0131n\u0131n azald\u0131\u011f\u0131n\u0131 g\u00f6sterebilir. Gen terapisi alan hastalar \u00fczerinde yap\u0131lan bir \u00e7al\u0131\u015fmada, CK seviyeleri tedaviden k\u0131sa bir s\u00fcre sonra yakla\u015f\u0131k 44% oran\u0131nda azalm\u0131\u015f ve ard\u0131ndan stabilize olmu\u015ftur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu t\u00fcr de\u011fi\u015fiklikler, motor fonksiyonlarda \u00f6l\u00e7\u00fclebilir iyile\u015fmelerden aylar hatta y\u0131llar \u00f6nce meydana gelebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu durum Duchenne kas distrofisinde \u00f6zellikle \u00f6nemlidir \u00e7\u00fcnk\u00fc:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u0130\u015flevsel gerileme yava\u015f yava\u015f ger\u00e7ekle\u015fir.<\/li>\n\n\n\n<li>Denemeler yaln\u0131zca 12-24 ay s\u00fcrebilir.<\/li>\n\n\n\n<li>Hasta say\u0131s\u0131 azd\u0131r.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dolay\u0131s\u0131yla, biyobelirte\u00e7ler biyolojik aktiviteye dair kritik kan\u0131tlar sunmaktad\u0131r.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"monitoring-safety-ast-and-alt\">G\u00fcvenli\u011fin \u0130zlenmesi: AST ve ALT<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biyobelirte\u00e7lerin raporlanmas\u0131n\u0131n bir di\u011fer \u00f6nemli nedeni de g\u00fcvenlik izlemesidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi i\u00e7in gen terapilerinde genellikle adeno-ili\u015fkili vir\u00fcs (AAV) vekt\u00f6rleri kullan\u0131l\u0131r. Bu vekt\u00f6rler genellikle g\u00fcvenli olsa da, ba\u011f\u0131\u015f\u0131kl\u0131k reaksiyonlar\u0131na veya karaci\u011fer toksisitesine neden olabilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu nedenle gen terapisi uygulamas\u0131ndan sonra AST ve ALT d\u00fczeyleri yak\u0131ndan izlenir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yak\u0131n zamanda yay\u0131nlanan bir vaka raporunda, AAV tabanl\u0131 gen terapisi sonras\u0131nda gecikmi\u015f karaci\u011fer hasar\u0131 tan\u0131mlanm\u0131\u015f olup, ALT ve AST d\u00fczeyleri imm\u00fcnosupresif tedavi uyguland\u0131ktan sonra ba\u015flang\u0131\u00e7 seviyelerine d\u00f6nmeden \u00f6nce \u00f6nemli \u00f6l\u00e7\u00fcde artm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca ALT\/CK oran\u0131n\u0131n, gen terapisi alan Duchenne hastalar\u0131nda karaci\u011fer hasar\u0131n\u0131 tespit etmek i\u00e7in erken bir biyobelirte\u00e7 olarak kullan\u0131labilece\u011fini \u00f6ne s\u00fcrd\u00fcler.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu biyobelirte\u00e7lerin kamuya a\u00e7\u0131k olarak raporlanmamas\u0131 durumunda, klinisyenler bu tedavilerin g\u00fcvenlik profilini tam olarak de\u011ferlendiremezler.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"dystrophin-the-most-important-biomarker\">Distrofin: En \u00d6nemli Biyobelirte\u00e7<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sonu\u00e7 olarak, bir\u00e7ok Duchenne tedavisinin amac\u0131 distrofini eski haline getirmektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu nedenle, distrofin d\u00fczeyleri klinik ara\u015ft\u0131rmalarda en \u00f6nemli de\u011ferlendirme noktalar\u0131ndan biri olmal\u0131d\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00f6l\u00e7\u00fcmler genellikle kas biyopsilerinden \u015fu y\u00f6ntemler kullan\u0131larak elde edilir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Western blot<\/li>\n\n\n\n<li>imm\u00fcnofloresans<\/li>\n\n\n\n<li>k\u00fctle spektrometrisi.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak distrofin verileri genellikle kar\u015f\u0131la\u015ft\u0131rmalar\u0131 zorla\u015ft\u0131ran \u015fekillerde sunulmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Distrofin pozitif liflerin y\u00fczdesi<\/li>\n\n\n\n<li>Normal kaslara g\u00f6re distrofin yo\u011funlu\u011fu<\/li>\n\n\n\n<li>Western blot y\u00fczdeleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Farkl\u0131 \u00e7al\u0131\u015fmalarda distrofin ekspresyonu farkl\u0131 y\u00f6ntemler veya normalle\u015ftirme teknikleri kullan\u0131larak rapor edilebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu standardizasyon eksikli\u011fi, yorumlamay\u0131 daha da karma\u015f\u0131k hale getiriyor.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"when-functional-outcomes-and-biomarkers-do-not-align\">Fonksiyonel Sonu\u00e7lar ve Biyobelirte\u00e7ler Uyumsuz Oldu\u011funda<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Baz\u0131 \u00e7al\u0131\u015fmalarda, fonksiyonel sonu\u00e7lar ve biyobelirte\u00e7 verileri farkl\u0131 hikayeler anlat\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Bir tedavi, distrofin ekspresyonunda art\u0131\u015f g\u00f6sterebilir ancak fonksiyonel iyile\u015fme s\u0131n\u0131rl\u0131 kalabilir.<\/li>\n\n\n\n<li>Fonksiyonel iyile\u015fmeler, belirgin biyobelirte\u00e7 de\u011fi\u015fiklikleri olmaks\u0131z\u0131n da ortaya \u00e7\u0131kabilir.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu tutars\u0131zl\u0131klar, her iki veri t\u00fcr\u00fcn\u00fcn de birlikte raporlanmas\u0131 gerekti\u011finin alt\u0131n\u0131 \u00e7izmektedir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Distrofin ekspresyonunu art\u0131ran ancak hen\u00fcz fonksiyonel fayda g\u00f6stermeyen bir tedavi, yine de hastal\u0131\u011f\u0131 de\u011fi\u015ftirici olabilir. Bu noktada odaklan\u0131lmas\u0131 gereken biyobelirte\u00e7, kreatin kinaz (CK) seviyesidir. <strong>Y\u00fcksek kreatin kinaz (CK) seviyeleri, devam eden kas hasar\u0131na i\u015faret eder.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6te yandan, biyokimyasal de\u011fi\u015fiklikler olmaks\u0131z\u0131n fonksiyonel skorlar\u0131 iyile\u015ftiren bir terapi, hastal\u0131k ilerlemesini de\u011fi\u015ftirmek yerine k\u0131sa vadeli semptomatik etkilere yol a\u00e7abilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-role-of-regulatory-agencies\">D\u00fczenleyici Kurumlar\u0131n Rol\u00fc<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ABD G\u0131da ve \u0130la\u00e7 \u0130daresi veya Avrupa \u0130la\u00e7 Ajans\u0131 gibi d\u00fczenleyici kurumlar, Duchenne tedavilerini de\u011ferlendirirken giderek daha fazla dolayl\u0131 biyobelirte\u00e7lere ba\u015fvurmaktad\u0131r. <a href=\"https:\/\/dmdwarrior.com\/tr\/why-elevidys-was-not-approved-by-the-european-medicines-agency-ema\/\" target=\"_blank\" rel=\"noreferrer noopener\">Elevidys Neden Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) Taraf\u0131ndan Onaylanmad\u0131?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak baz\u0131 tedavilerin onaylanmas\u0131 da tart\u0131\u015fmalara yol a\u00e7m\u0131\u015ft\u0131r. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/why-does-the-fda-approve-dmd-therapies-that-fail-in-clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">FDA Klinik \u00c7al\u0131\u015fmalarda Ba\u015far\u0131s\u0131z Olan DMD Terapilerini Neden Onayl\u0131yor?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Baz\u0131 uzmanlar, \u00f6zellikle NSAA gibi birincil sonu\u00e7 \u00f6l\u00e7\u00fctlerine belirli \u00e7al\u0131\u015fmalarda ula\u015f\u0131lamad\u0131\u011f\u0131 durumlarda, klinik \u00e7al\u0131\u015fma verilerinin uzun vadeli fayda konusunda yeterli kan\u0131t sa\u011flay\u0131p sa\u011flamad\u0131\u011f\u0131n\u0131 sorgulam\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu tart\u0131\u015fma, \u015feffaf biyobelirte\u00e7 raporlamas\u0131n\u0131n \u00f6nemini vurgulamaktad\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-patient-perspective\">Hasta Bak\u0131\u015f A\u00e7\u0131s\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisinden etkilenen aileler i\u00e7in, klinik deneme duyurular\u0131 genellikle b\u00fcy\u00fck bir umut yarat\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak eksik veriler kafa kar\u0131\u015f\u0131kl\u0131\u011f\u0131na yol a\u00e7abilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hastalar \u015funlar\u0131 bilmeyi hak ediyor:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>tedavilerin kas hasar\u0131n\u0131 azalt\u0131p azaltmad\u0131\u011f\u0131<\/li>\n\n\n\n<li>distrofin \u00fcretiminin artmas\u0131<\/li>\n\n\n\n<li>biyobelirte\u00e7lerin normale d\u00f6n\u00fcp d\u00f6nmedi\u011fi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eeffaf raporlama, hastalar\u0131n klinik ara\u015ft\u0131rmalara kat\u0131lma veya yeni onaylanm\u0131\u015f tedavileri alma konusunda bilin\u00e7li kararlar vermelerine yard\u0131mc\u0131 olur.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-need-for-standardized-biomarker-reporting\">Biyobelirte\u00e7 Raporlamas\u0131n\u0131n Standartla\u015ft\u0131r\u0131lmas\u0131na Duyulan \u0130htiya\u00e7<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne ara\u015ft\u0131rma toplulu\u011fu, klinik \u00e7al\u0131\u015fmalarda biyobelirte\u00e7 raporlamas\u0131 i\u00e7in standartla\u015ft\u0131r\u0131lm\u0131\u015f k\u0131lavuzlar benimsemeyi d\u00fc\u015f\u00fcnmelidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunlar \u015funlar\u0131 i\u00e7erebilir:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A\u015fa\u011f\u0131dakilerin bildirilmesi zorunludur:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kreatin Kinaz (CK) seviyeleri<\/li>\n\n\n\n<li>AST ve ALT d\u00fczeyleri<\/li>\n\n\n\n<li>Distrofin ekspresyon seviyeleri<\/li>\n\n\n\n<li>Bireysel hasta de\u011fi\u015fkenli\u011fi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Standartla\u015ft\u0131r\u0131lm\u0131\u015f \u00f6l\u00e7\u00fcm y\u00f6ntemleri<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tutarl\u0131 laboratuvar y\u00f6ntemleri, denemeler aras\u0131nda kar\u015f\u0131la\u015ft\u0131rmalar\u0131 kolayla\u015ft\u0131racakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Uzun vadeli biyobelirte\u00e7 takibi<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi yava\u015f ilerledi\u011fi i\u00e7in uzun vadeli biyobelirte\u00e7 takibi \u015fartt\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"toward-greater-transparency-in-duchenne-research\">Duchenne Ara\u015ft\u0131rmalar\u0131nda Daha Fazla \u015eeffafl\u0131\u011fa Do\u011fru<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne tedavisindeki h\u0131zl\u0131 yenilik temposu cesaret verici.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak \u015feffafl\u0131k, yeniliklere ayak uydurmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ara\u015ft\u0131rmalarda a\u015fa\u011f\u0131daki hususlar\u0131n eksiksiz olarak raporlanmas\u0131na \u00f6ncelik verilmelidir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>biyokimyasal biyobelirte\u00e7ler<\/li>\n\n\n\n<li>molek\u00fcler u\u00e7 noktalar<\/li>\n\n\n\n<li>fonksiyonel sonu\u00e7lar (NSAA)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne toplulu\u011fu ancak bu veri k\u00fcmelerini birle\u015ftirerek yeni ortaya \u00e7\u0131kan tedavilerin etkinli\u011fini ger\u00e7ekten de\u011ferlendirebilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions-faq-about-duchenne-clinical-trials-and-biomarkers\">Duchenne Klinik \u00c7al\u0131\u015fmalar\u0131 ve Biyobelirte\u00e7leri Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular (SSS)<\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1773236242350\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Duchenne kas distrofisi klinik \u00e7al\u0131\u015fmalar\u0131nda biyobelirte\u00e7ler neden \u00f6nemlidir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Biyobelirte\u00e7ler, doktorlar\u0131n ve ara\u015ft\u0131rmac\u0131lar\u0131n bir hastal\u0131\u011f\u0131n nas\u0131l ilerledi\u011fini ve bir tedavinin i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131 anlamalar\u0131na yard\u0131mc\u0131 olan \u00f6l\u00e7\u00fclebilir biyolojik g\u00f6stergelerdir. Duchenne kas distrofisinde (DMD), kreatin kinaz (CK), AST, ALT ve distrofin seviyeleri gibi biyobelirte\u00e7ler, kas hasar\u0131 veya iyile\u015fmesine dair do\u011frudan biyokimyasal kan\u0131t sa\u011flar.<\/p>\n<p>North Star Ambulatory Assessment (NSAA) gibi fonksiyonel testler fiziksel yetenekleri \u00f6l\u00e7erken, biyobelirte\u00e7ler kas h\u00fccrelerinin i\u00e7inde neler olup bitti\u011fini ortaya koymaktad\u0131r. Her iki veri t\u00fcr\u00fcn\u00fcn birle\u015ftirilmesi, tedavi etkinli\u011fine dair daha eksiksiz bir tablo sunar.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236258234\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Kreatin kinaz (CK) nedir ve Duchenne kas distrofisinde neden \u00f6nemlidir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Kreatin kinaz (CK), kas h\u00fccrelerinde bulunan bir enzimdir. Kas lifleri hasar g\u00f6rd\u00fc\u011f\u00fcnde, CK kan dola\u015f\u0131m\u0131na s\u0131zar ve bu da kan testlerinde CK seviyelerinin y\u00fckselmesine neden olur.<\/p>\n<p>Duchenne kas distrofisi olan \u00e7ocuklarda, kaslar\u0131 s\u00fcrekli olarak par\u00e7aland\u0131\u011f\u0131 i\u00e7in CK seviyeleri normalden 10-100 kat daha y\u00fcksek olabilir. E\u011fer bir tedavi kas h\u00fccrelerini ba\u015far\u0131l\u0131 bir \u015fekilde korursa, CK seviyeleri zamanla d\u00fc\u015febilir.<\/p>\n<p>Bu nedenle CK, Duchenne ara\u015ft\u0131rmalar\u0131nda en s\u0131k izlenen biyobelirte\u00e7lerden biridir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236281023\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Duchenne kas distrofisi hastalar\u0131nda AST ve ALT d\u00fczeyleri neden s\u0131kl\u0131kla y\u00fcksektir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>AST (aspartat aminotransferaz) ve ALT (alanin aminotransferaz) genellikle karaci\u011fer fonksiyon testleriyle ili\u015fkilendirilen enzimlerdir. Bununla birlikte, bu enzimler kas dokusunda da bulunur.<\/p>\n<p>Duchenne kas distrofisinde, kas y\u0131k\u0131m\u0131 AST ve ALT&#039;yi kan dola\u015f\u0131m\u0131na salar ve bu da karaci\u011fer sa\u011fl\u0131kl\u0131 olsa bile seviyelerinin y\u00fckselmesine neden olabilir.<\/p>\n<p>Klinik ara\u015ft\u0131rmalar s\u0131ras\u0131nda AST ve ALT d\u00fczeylerinin izlenmesi \u00f6zellikle \u00f6nemlidir \u00e7\u00fcnk\u00fc baz\u0131 gen terapileri karaci\u011fer fonksiyonunu ge\u00e7ici olarak etkileyebilir. Bu biyobelirte\u00e7ler, doktorlar\u0131n hem kas hasar\u0131n\u0131 hem de tedavi g\u00fcvenli\u011fini de\u011ferlendirmelerine yard\u0131mc\u0131 olur.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236299747\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Dystrofin nedir ve Duchenne kas distrofisi tedavilerinde neden \u00f6nemlidir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Distrofin, kas h\u00fccrelerinin kas\u0131lma s\u0131ras\u0131nda stabilize olmas\u0131na yard\u0131mc\u0131 olan bir proteindir. Duchenne kas distrofisinde, distrofin genindeki mutasyonlar v\u00fccudun bu proteini \u00fcretmesini engeller.<\/p>\n<p>Distrofin olmadan kas h\u00fccreleri k\u0131r\u0131lgan hale gelir ve kolayca hasar g\u00f6r\u00fcr, bu da ilerleyici kas dejenerasyonuna yol a\u00e7ar.<\/p>\n<p>Gen terapisi ve ekzon atlama terapileri de dahil olmak \u00fczere bir\u00e7ok yeni Duchenne tedavisi, distrofin \u00fcretimini geri kazand\u0131rmay\u0131 ama\u00e7lamaktad\u0131r. Bu nedenle, kas dokusundaki distrofin seviyelerinin \u00f6l\u00e7\u00fclmesi, bir tedavinin molek\u00fcler d\u00fczeyde i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131 belirlemenin en \u00f6nemli yollar\u0131ndan biridir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236320298\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Baz\u0131 klinik ara\u015ft\u0131rma duyurular\u0131n\u0131n neden \u00e7o\u011funlukla NSAA puanlar\u0131na odaklanmas\u0131n\u0131n sebebi nedir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Kuzey Y\u0131ld\u0131z\u0131 Y\u00fcr\u00fcme De\u011ferlendirmesi (NSAA), Duchenne kas distrofisi olan y\u00fcr\u00fcyebilen erkek \u00e7ocuklar\u0131n motor becerilerini \u00f6l\u00e7en, yayg\u0131n olarak kullan\u0131lan bir fonksiyonel testtir.<\/p>\n<p>Ayakta durma, y\u00fcr\u00fcme ve t\u0131rmanma gibi ger\u00e7ek d\u00fcnyadaki fiziksel yetenekleri de\u011ferlendirdi\u011fi i\u00e7in bir\u00e7ok klinik \u00e7al\u0131\u015fmada \u00f6nemli bir sonu\u00e7 \u00f6l\u00e7\u00fct\u00fc olarak kabul edilir.<\/p>\n<p>Ancak, NSAA sonu\u00e7lar\u0131 ya\u015f, steroid kullan\u0131m\u0131 ve do\u011fal b\u00fcy\u00fcme gibi \u00e7e\u015fitli fakt\u00f6rlerden etkilenebilir. Bu nedenle, uzmanlar NSAA sonu\u00e7lar\u0131n\u0131n her zaman CK d\u00fczeyleri ve distrofin ekspresyonu gibi biyomarker verileriyle birlikte yorumlanmas\u0131 gerekti\u011fini vurgulamaktad\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236346480\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Tedavi i\u015fe yaramasa bile NSAA puanlar\u0131 iyile\u015febilir mi?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet, bu baz\u0131 durumlarda m\u00fcmk\u00fcnd\u00fcr. Duchenne kas distrofisi olan k\u00fc\u00e7\u00fck \u00e7ocuklarda, b\u00fcy\u00fcd\u00fck\u00e7e ge\u00e7ici olarak g\u00fc\u00e7 ve koordinasyonda iyile\u015fmeler g\u00f6r\u00fclebilir. Steroid tedavisi de bir s\u00fcre i\u00e7in motor performans\u0131n\u0131 iyile\u015ftirebilir.<\/p>\n<p>Bu fakt\u00f6rler nedeniyle, NSAA skorlar\u0131ndaki iyile\u015fmeler her zaman bir tedavinin hastal\u0131\u011f\u0131 yava\u015flatt\u0131\u011f\u0131n\u0131 kan\u0131tlamaz. Biyobelirte\u00e7ler, bir tedavinin ger\u00e7ekten kas h\u00fccrelerini koruyup korumad\u0131\u011f\u0131n\u0131 veya distrofini geri kazand\u0131r\u0131p kazand\u0131rmad\u0131\u011f\u0131n\u0131 do\u011frulamaya yard\u0131mc\u0131 olur.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236364060\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Baz\u0131 klinik ara\u015ft\u0131rmalar neden ayr\u0131nt\u0131l\u0131 biyobelirte\u00e7 sonu\u00e7lar\u0131n\u0131 yay\u0131nlam\u0131yor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Bunun birka\u00e7 nedeni olabilir. Bazen erken d\u00f6nem deneme g\u00fcncellemeleri veya \u015firket bas\u0131n b\u00fcltenleri, tam veri setleri hen\u00fcz analiz edilirken yaln\u0131zca se\u00e7ilmi\u015f sonu\u00e7lara odaklan\u0131r. Di\u011fer durumlarda, biyobelirte\u00e7 verileri daha sonra bilimsel konferanslarda veya hakemli yay\u0131nlarda yer alabilir.<\/p>\n<p>Ancak bir\u00e7ok ara\u015ft\u0131rmac\u0131 ve hasta haklar\u0131 savunucusu, ailelerin, doktorlar\u0131n ve bilim insanlar\u0131n\u0131n deneysel tedavilerin nas\u0131l i\u015fledi\u011fini daha iyi anlamalar\u0131 i\u00e7in daha fazla \u015feffafl\u0131\u011f\u0131n gerekli oldu\u011funa inan\u0131yor.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236373471\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Klinik \u00e7al\u0131\u015fmalarda distrofin d\u00fczeyleri nas\u0131l \u00f6l\u00e7\u00fcl\u00fcr?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Distrofin d\u00fczeyleri genellikle klinik \u00e7al\u0131\u015fmalar s\u0131ras\u0131nda hastalardan al\u0131nan kas biyopsisi \u00f6rnekleri kullan\u0131larak \u00f6l\u00e7\u00fcl\u00fcr. A\u015fa\u011f\u0131dakiler de dahil olmak \u00fczere \u00e7e\u015fitli laboratuvar y\u00f6ntemleri kullan\u0131labilir:<\/p>\n<p>\u2022 Western blot analizi<sup data-fn=\"2a669490-fc2d-43c7-baa0-9fad144e0028\" class=\"fn\"><a id=\"2a669490-fc2d-43c7-baa0-9fad144e0028-link\" href=\"#2a669490-fc2d-43c7-baa0-9fad144e0028\">2<\/a><\/sup><br \/>\u2022 \u0130mm\u00fcnofloresan mikroskopi<br \/>\u2022 K\u00fctle spektrometrisi<\/p>\n<p>Her y\u00f6ntem distrofin \u00f6l\u00e7\u00fcm\u00fcn\u00fc biraz farkl\u0131 \u015fekillerde yapar; bu da bazen \u00e7al\u0131\u015fmalar aras\u0131nda kar\u015f\u0131la\u015ft\u0131rma yapmay\u0131 zorla\u015ft\u0131rabilir. Bu \u00f6l\u00e7\u00fcm y\u00f6ntemlerinin standardizasyonu, Duchenne ara\u015ft\u0131rma toplulu\u011fu i\u00e7inde devam eden bir hedeftir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236409734\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">D\u00fc\u015f\u00fck CK seviyeleri Duchenne tedavisinin i\u015fe yarad\u0131\u011f\u0131 anlam\u0131na m\u0131 gelir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>D\u00fc\u015f\u00fck CK seviyeleri, kas hasar\u0131n\u0131n azald\u0131\u011f\u0131n\u0131n olumlu bir i\u015fareti olabilir. Bununla birlikte, CK seviyeleri tek ba\u015f\u0131na bir tedavinin etkili oldu\u011funu kan\u0131tlayamaz.<\/p>\n<p>Ara\u015ft\u0131rmac\u0131lar genellikle CK e\u011filimlerini di\u011fer biyobelirte\u00e7ler, distrofin ekspresyon verileri, g\u00f6r\u00fcnt\u00fcleme \u00e7al\u0131\u015fmalar\u0131 ve fonksiyonel testlerle birlikte de\u011ferlendirirler. Birden fazla g\u00f6stergede g\u00f6r\u00fclen iyile\u015fmelerin birle\u015fimi, bir tedavinin faydal\u0131 olabilece\u011fine dair daha g\u00fc\u00e7l\u00fc kan\u0131tlar sunar.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236430411\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Aileler klinik ara\u015ft\u0131rma sonu\u00e7lar\u0131 hakk\u0131nda yaln\u0131zca bas\u0131n b\u00fcltenlerine mi g\u00fcvenmeli?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Bas\u0131n b\u00fcltenleri faydal\u0131 g\u00fcncellemeler sa\u011flayabilir, ancak genellikle bir \u00e7al\u0131\u015fman\u0131n yaln\u0131zca se\u00e7ilmi\u015f b\u00f6l\u00fcmlerini \u00f6zetlerler. Bir tedavinin etkinli\u011fi ve g\u00fcvenli\u011fi hakk\u0131nda tam bir anlay\u0131\u015fa sahip olmak i\u00e7in aileler ayr\u0131ca \u015funlara da dikkat etmelidir:<\/p>\n<p>\u2022 hakemli bilimsel yay\u0131nlar<br \/>\u2022 konferans sunumlar\u0131<br \/>\u2022 klinik ara\u015ft\u0131rma kay\u0131t verileri<br \/>\u2022 n\u00f6rom\u00fcsk\u00fcler uzmanlardan al\u0131nan bilgiler.<\/p>\n<p>Duchenne kas distrofisi konusunda bilgili bir sa\u011fl\u0131k uzman\u0131na dan\u0131\u015fmak, klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131n\u0131 daha do\u011fru yorumlamaya da yard\u0131mc\u0131 olabilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236472719\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Aileler, Duchenne kas distrofisi klinik deneme sonu\u00e7lar\u0131n\u0131 de\u011ferlendirirken nelere dikkat etmelidir?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Yeni klinik ara\u015ft\u0131rma verilerini incelerken, aileler birka\u00e7 \u00f6nemli fakt\u00f6r\u00fc g\u00f6z \u00f6n\u00fcnde bulundurmak isteyebilir:<\/p>\n<p>\u2022 NSAA gibi fonksiyonel testlerdeki de\u011fi\u015fiklikler<br \/>\u2022 CK, AST ve ALT dahil olmak \u00fczere biyobelirte\u00e7 e\u011filimleri<br \/>\u2022 distrofin ekspresyon seviyeleri<br \/>\u2022 G\u00fcvenlik ve yan etkiler<br \/>\u2022 Uzun vadeli takip verileri.<\/p>\n<p>T\u00fcm bu unsurlar\u0131 birlikte de\u011ferlendirmek, bir tedavinin hastalara ger\u00e7ekten fayda sa\u011flay\u0131p sa\u011flamayaca\u011f\u0131na dair daha dengeli bir anlay\u0131\u015f sunar.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1773236513181\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Gelecekteki Duchenne \u00e7al\u0131\u015fmalar\u0131nda biyobelirte\u00e7 raporlamas\u0131 daha yayg\u0131n hale gelecek mi?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Bir\u00e7ok uzman bunun b\u00f6yle olaca\u011f\u0131na inan\u0131yor. Duchenne kas distrofisi tedavisinin karma\u015f\u0131kla\u015fmas\u0131yla birlikte, ara\u015ft\u0131rmac\u0131lar ve d\u00fczenleyici kurumlar kapsaml\u0131 veri raporlamas\u0131na giderek daha fazla \u00f6nem veriyor.<\/p>\n<p>Standartla\u015ft\u0131r\u0131lm\u0131\u015f biyobelirte\u00e7 raporlamas\u0131, \u015feffafl\u0131\u011f\u0131 art\u0131rmaya, tedaviler aras\u0131nda daha iyi kar\u015f\u0131la\u015ft\u0131rmalar yap\u0131lmas\u0131na ve nihayetinde Duchenne kas distrofisi i\u00e7in etkili tedavilerin geli\u015ftirilmesini h\u0131zland\u0131rmaya yard\u0131mc\u0131 olabilir.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi y\u0131k\u0131c\u0131 bir hastal\u0131k olmaya devam ediyor, ancak yeni gen terapileri ve ekzon atlama tedavileri umut veriyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak umut, bilimsel titizlik ve \u015feffafl\u0131kla birlikte gelmelidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">NSAA gibi fonksiyonel \u00f6l\u00e7\u00fcmler \u00f6nemlidir, ancak tek ba\u015flar\u0131na tedavi ba\u015far\u0131s\u0131n\u0131n kan\u0131t\u0131 olarak kabul edilemezler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisinde kreatin kinaz (CK), AST, ALT ve distrofin d\u00fczeyleri gibi biyobelirte\u00e7ler, tedavilerin hastal\u0131k s\u00fcrecini ger\u00e7ekten de\u011fi\u015ftirip de\u011fi\u015ftirmedi\u011fi konusunda \u00e7ok \u00f6nemli bilgiler sa\u011flar.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hastalar\u0131n, klinisyenlerin ve ara\u015ft\u0131rmac\u0131lar\u0131n bu tedavileri do\u011fru bir \u015fekilde de\u011ferlendirebilmelerini sa\u011flamak i\u00e7in, klinik \u00e7al\u0131\u015fmalar\u0131n kapsaml\u0131 biyobelirte\u00e7 raporlamas\u0131na ba\u011fl\u0131 kalmas\u0131 gerekmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u015feffafl\u0131k olmadan, Duchenne toplulu\u011fu eksik kan\u0131tlara dayanarak karar verme riskiyle kar\u015f\u0131 kar\u015f\u0131ya kalacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sources-and-academic-references\">Kaynaklar ve Akademik Referanslar<\/h2>\n\n\n<ol class=\"wp-block-footnotes\"><li id=\"a8963fdf-1c4d-4eae-b955-4fcf316dd517\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10657716\/\" target=\"_blank\" rel=\"noopener\">Duchenne Kas Distrofisinde Biyobelirte\u00e7ler: Mevcut Durum ve Gelecek Y\u00f6nelimler<\/a> <a href=\"#a8963fdf-1c4d-4eae-b955-4fcf316dd517-link\" aria-label=\"Dipnot tak\u0131m\u0131na atla 1\">\u21a9\ufe0e<\/a><\/li><li id=\"2a669490-fc2d-43c7-baa0-9fad144e0028\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10034579\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u0130nsan \u0130skelet Kas Biyopsilerinde Mini-Distrofini Kantitatif Olarak Belirlemek i\u00e7in Bir Western Blot Y\u00f6nteminin Geli\u015ftirilmesi ve Do\u011frulanmas\u0131<\/a> <a href=\"#2a669490-fc2d-43c7-baa0-9fad144e0028-link\" aria-label=\"Dipnot tak\u0131m\u0131na atla 2\">\u21a9\ufe0e<\/a><\/li><\/ol>","protected":false},"excerpt":{"rendered":"<p>So why do many DMD clinical trials avoid clearly reporting these key biomarkers? This article examines why CK, AST, ALT, and dystrophin data matter\u2014and why families pursuing treatment options should demand full transparency. Duchenne muscular dystrophy (DMD) is one of the most devastating genetic neuromuscular disorders, characterized by progressive muscle degeneration caused by mutations in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6734,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"[{\"content\":\"<a href=\\\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10657716\/\\\">Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions<\/a>\",\"id\":\"a8963fdf-1c4d-4eae-b955-4fcf316dd517\"},{\"content\":\"<a href=\\\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10034579\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Development and Validation of a Western Blot Method to Quantify Mini-Dystrophin in Human Skeletal Muscle Biopsies<\/a>\",\"id\":\"2a669490-fc2d-43c7-baa0-9fad144e0028\"}]"},"categories":[282],"tags":[522,523],"class_list":["post-6725","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-biomarkers","tag-duchenne-biomarkers"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=6725"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/6734"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=6725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=6725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=6725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}